Vivani Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $97.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | $-0.11 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | $-0.10 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | $-0.12 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | Before market open | – | $-0.12 | – |
Press releases
Announcements Vivani Medical filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a
Material agreement · Other events · EX-99.1 to Form 8-K
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Reports Fourth Quarter and Full Year 2025
Results of operations · EX-99.1 to Form 8-K
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vivani Medical Announces Record Date for Spin -off of Cortigent
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight M anagement
Other events · EX-99.1 to Form 8-K
Vivani Medical Provides Business Update Including $10M Equity
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM- 139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks
Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Appoint s Anthony Baldor as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical Provides Business Update Including $3M Equity
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
Other events · EX-99.1 to Form 8-K
Vivani Medical Provides Business Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Vivani Medical Announces $8.25M Private
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM -139 Semaglutide Implant, with Potential for Once-Yearly Dosing
Other events · EX-99.1 to Form 8-K
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vivani Medical A chieves First Implant and Full Enrollment in the First - in - Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vivani Medical Provides Business Update Including $ 5 M Equity
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.Nasdaq: VANI WWW.Vivani.com
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
V ivani M edical to Present at the Partnership Opportunities in Drug De livery (PODD) Event and ThinkEquity Conference in October 2024
Other events · EX-99.1 to Form 8-K
V ivani Medical Receives Regulatory Approval to Initiate First in Human
Other events · EX-99.1 to Form 8-K
V ivani M edical to Present at the Emerging Growth Conference
Other events · EX-99.1 to Form 8-K
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long- Acting GLP-1 Implant
Other events · EX-99.1 to Form 8-K
Vivani Medical Provides Business Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K